{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:42Z","timestamp":1792831062772,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["TYH2024310"],"award-info":[{"award-number":["TYH2024310"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Helsinki","id":[{"id":"https:\/\/ror.org\/040af2s02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40265-026-02386-y","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:59:07Z","timestamp":1790305147000},"page":"1781-1794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized Treatment of Hemophilia: Matching Therapies to Patient Needs in a Rapidly Evolving Landscape"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-6564","authenticated-orcid":false,"given":"Timea","family":"Szanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-3094","authenticated-orcid":false,"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"Suppl 6","key":"2386_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"issue":"4","key":"2386_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102879","volume":"9","author":"A Srivastava","year":"2025","unstructured":"Srivastava A, Mahlangu J, Pipe SW. Guidelines for management of haemophilia\u2014why, what, and how? Res Pract Thromb Haemost. 2025;9(4):102879. https:\/\/doi.org\/10.1016\/j.rpth.2025.102879.","journal-title":"Res Pract Thromb Haemost"},{"key":"2386_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103678","volume":"174","author":"C Hermans","year":"2022","unstructured":"Hermans C, Reding MT, Astermark J, Klamroth R, Mancuso ME. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: a critical review from the physician\u2019s perspective. Crit Rev Oncol Hematol. 2022;174:103678. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103678.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2386_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","volume":"123","author":"J Mahlangu","year":"2014","unstructured":"Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317\u201325. https:\/\/doi.org\/10.1182\/blood-2013-10-529974.","journal-title":"Blood"},{"issue":"3","key":"2386_CR5","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1111\/hae.14297","volume":"27","author":"MT Reding","year":"2021","unstructured":"Reding MT, Pabinger I, Holme PA, Poulsen L, Negrier C, Chalasani P, et al. Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia. 2021;27(3):e347\u201356. https:\/\/doi.org\/10.1111\/hae.14297.","journal-title":"Haemophilia"},{"issue":"9","key":"2386_CR6","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","volume":"126","author":"BA Konkle","year":"2015","unstructured":"Konkle BA, Stasyshyn O, Chowdary P, Bevan DH, Mant T, Shima M, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9):1078\u201385. https:\/\/doi.org\/10.1182\/blood-2015-03-630897.","journal-title":"Blood"},{"issue":"4","key":"2386_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388(4):310\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2209226.","journal-title":"N Engl J Med"},{"issue":"24","key":"2386_CR8","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","volume":"369","author":"JS Powell","year":"2013","unstructured":"Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1305074.","journal-title":"N Engl J Med"},{"issue":"14","key":"2386_CR9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","volume":"127","author":"E Santagostino","year":"2016","unstructured":"Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761\u20139. https:\/\/doi.org\/10.1182\/blood-2015-09-669234.","journal-title":"Blood"},{"issue":"3","key":"2386_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17512433.2026.2636123","volume":"19","author":"V Eduarda Alves de Jesus","year":"2026","unstructured":"Eduarda Alves de Jesus V, Lamounier de Almeida D, Muniz J\u00fanior RL, Alvares-Teodoro J, Pierce GF, Camelo RM. Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update. Expert Rev Clin Pharmacol. 2026;19(3):219\u201338. https:\/\/doi.org\/10.1080\/17512433.2026.2636123.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"2386_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1703068.","journal-title":"N Engl J Med"},{"issue":"24","key":"2386_CR12","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jim\u00e9nez-Yuste V, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127\u201338. https:\/\/doi.org\/10.1182\/blood.2019001869.","journal-title":"Blood"},{"issue":"9","key":"2386_CR13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1803550.","journal-title":"N Engl J Med"},{"key":"2386_CR14","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"SW Pipe","year":"2019","unstructured":"Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295\u2013305. https:\/\/doi.org\/10.1016\/S2352-3026(19)30054-7.","journal-title":"Lancet Haematol"},{"issue":"17","key":"2386_CR15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2517384","volume":"394","author":"ME Mancuso","year":"2026","unstructured":"Mancuso ME, Chan AKC, Shanmukhaiah C, Lyu CJ, Zdziarska J, Mahlangu J, et al. Mim8 bispecific antibody prophylaxis in hemophilia A with or without inhibitors. N Engl J Med. 2026;394(17):1696\u2013709. https:\/\/doi.org\/10.1056\/NEJMoa2517384.","journal-title":"N Engl J Med"},{"issue":"12","key":"2386_CR16","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.3324\/haematol.2025.288245","volume":"110","author":"Q Van Thillo","year":"2025","unstructured":"Van Thillo Q, Hermans C. Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties. Haematologica. 2025;110(12):2902\u201312. https:\/\/doi.org\/10.3324\/haematol.2025.288245.","journal-title":"Haematologica"},{"issue":"10386","key":"2386_CR17","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","volume":"401","author":"G Young","year":"2023","unstructured":"Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You CW, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023;401(10386):1427\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(23)00284-2.","journal-title":"Lancet"},{"issue":"5","key":"2386_CR18","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","volume":"10","author":"A Srivastava","year":"2023","unstructured":"Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023;10(5):e322\u201332. https:\/\/doi.org\/10.1016\/S2352-3026(23)00037-6.","journal-title":"Lancet Haematol"},{"issue":"9","key":"2386_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2216455","volume":"389","author":"T Matsushita","year":"2023","unstructured":"Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389(9):783\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2216455.","journal-title":"N Engl J Med"},{"issue":"12","key":"2386_CR20","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1016\/j.rpth.2025.102705","volume":"11","author":"P Chowdary","year":"2024","unstructured":"Chowdary P, Angchaisuksiri P, Apte S, Astermark J, Benson G, Chan AKC, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024;11(12):e891\u2013904. https:\/\/doi.org\/10.1016\/j.rpth.2025.102705.","journal-title":"Lancet Haematol."},{"issue":"9","key":"2386_CR21","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/blood.2025031065","volume":"147","author":"D Matino","year":"2026","unstructured":"Matino D, Acharya SS, Taylor CT, Sun P, Agathon D, Raje S, et al. Efficacy and safety of marstacimab prophylaxis in hemophilia A\/B with inhibitors: results from the phase 3 BASIS trial. Blood. 2026;147(9):920\u201331. https:\/\/doi.org\/10.1182\/blood.2025031065.","journal-title":"Blood"},{"issue":"14","key":"2386_CR22","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood.2024027468","volume":"146","author":"D Matino","year":"2025","unstructured":"Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, et al. Marstacimab prophylaxis in hemophilia A\/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025;146(14):1654\u201363. https:\/\/doi.org\/10.1182\/blood.2024027468.","journal-title":"Blood"},{"issue":"10","key":"2386_CR23","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1182\/bloodadvances.2026020150","volume":"10","author":"W Miesbach","year":"2026","unstructured":"Miesbach W, Herzog R. Six-year FIX-padua gene therapy in hemophilia B. Blood Adv. 2026;10(10):3715\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2026020150.","journal-title":"Blood Adv"},{"issue":"23","key":"2386_CR24","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","volume":"8","author":"SR Deshpande","year":"2024","unstructured":"Deshpande SR, Joseph K, Tong J, Chen Y, Pishko A, Cuker A. Adeno-associated virus-based gene therapy for hemophilia A and B: a systematic review and meta-analysis. Blood Adv. 2024;8(23):5957\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2024014111.","journal-title":"Blood Adv"},{"issue":"1","key":"2386_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/all.70207","volume":"31","author":"J Chapin","year":"2025","unstructured":"Chapin J, \u00c1lvarez Rom\u00e1n MT, Ayash-Rashkovsky M, Diogo D, Kenniston J, Lopez-Jaime FJ, et al. A phase 1\/2 safety and efficacy study of TAK-754 gene therapy: the challenge of achieving durable factor VIII expression in haemophilia A clinical trials. Haemophilia. 2025;31(1):108\u201317. https:\/\/doi.org\/10.1111\/all.70207.","journal-title":"Haemophilia"},{"issue":"8","key":"2386_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou SC, Ozelo MC, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388(8):694\u2013705. https:\/\/doi.org\/10.1056\/NEJMoa2211075.","journal-title":"N Engl J Med"},{"issue":"8","key":"2386_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2211644.","journal-title":"N Engl J Med"},{"issue":"5","key":"2386_CR28","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.jtha.2024.11.015","volume":"23","author":"G Young","year":"2025","unstructured":"Young G, Lassila R, Mason J, Prasca S. Deconstructing the ISTH hemophilia guidelines for the clinician. J Thromb Haemost. 2025;23(5):1483\u201395. https:\/\/doi.org\/10.1016\/j.jtha.2024.11.015.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 4","key":"2386_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/hae.14551","volume":"28","author":"ME Mancuso","year":"2022","unstructured":"Mancuso ME, Apte S, Hermans C. Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022. Haemophilia. 2022;28(Suppl 4):93\u2013102. https:\/\/doi.org\/10.1111\/hae.14551.","journal-title":"Haemophilia"},{"issue":"Suppl 3","key":"2386_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/hae.13978","volume":"27","author":"C Hermans","year":"2021","unstructured":"Hermans C, Apte S, Santagostino E. Invasive procedures in patients with haemophilia: review of low-dose protocols and experience with extended half-life FVIII and FIX concentrates and non-replacement therapies. Haemophilia. 2021;27(Suppl 3):46\u201352. https:\/\/doi.org\/10.1111\/hae.13978.","journal-title":"Haemophilia"},{"issue":"5","key":"2386_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/hae.14585","volume":"28","author":"AE Lehtinen","year":"2022","unstructured":"Lehtinen AE, Baghaei F, Astermark J, Holme PA. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: real-world experience in the Nordic countries. Haemophilia. 2022;28(5):713\u20139. https:\/\/doi.org\/10.1111\/hae.14585.","journal-title":"Haemophilia"},{"issue":"24","key":"2386_CR32","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","volume":"6","author":"R Kruse-Jarres","year":"2022","unstructured":"Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, Chebon S, Doral MY, et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1\u20134 studies. Blood Adv. 2022;6(24):6140\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2022007458.","journal-title":"Blood Adv"},{"issue":"1","key":"2386_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1182\/hematology.2022000387","volume":"2022","author":"JN Poston","year":"2022","unstructured":"Poston JN, Kruse-Jarres R. Perioperative hemostasis for patients with hemophilia. Hematology Am Soc Hematol Educ Program. 2022;2022(1):586\u201393. https:\/\/doi.org\/10.1182\/hematology.2022000387.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2386_CR34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/hematology.2025000773","volume":"2025","author":"M Lewandowska","year":"2025","unstructured":"Lewandowska M, Lim MY. The aging hemophilia patient. Hematol Am Soc Hematol Educ Program. 2025;2025(1):674\u201381. https:\/\/doi.org\/10.1182\/hematology.2025000773.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"17","key":"2386_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175121","volume":"13","author":"C K\u00f6nigs","year":"2024","unstructured":"K\u00f6nigs C, Motwani J, Jim\u00e9nez-Yuste V, Blatn\u00fd J. Teenagers and adolescents with hemophilia-need for a specific approach. J Clin Med. 2024;13(17):5121. https:\/\/doi.org\/10.3390\/jcm13175121.","journal-title":"J Clin Med"},{"issue":"Suppl 3","key":"2386_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/hae.14976","volume":"30","author":"ME Mancuso","year":"2024","unstructured":"Mancuso ME, Croteau SE, Klamroth R. Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies. Haemophilia. 2024;30(Suppl 3):39\u201344. https:\/\/doi.org\/10.1111\/hae.14976.","journal-title":"Haemophilia"},{"issue":"Suppl 3","key":"2386_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/hae.14982","volume":"30","author":"SL Meeks","year":"2024","unstructured":"Meeks SL, Zimowski KL. Haemophilia in the era of novel therapies: where do inhibitors feature in the new landscape? Haemophilia. 2024;30(Suppl 3):95\u2013102. https:\/\/doi.org\/10.1111\/hae.14982.","journal-title":"Haemophilia"},{"issue":"3","key":"2386_CR38","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1111\/hae.14010","volume":"27","author":"C Escuriola-Ettingshausen","year":"2021","unstructured":"Escuriola-Ettingshausen C, Auerswald G, K\u00f6nigs C, Kurnik K, Scholz U, Klamroth R, et al. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: recommendations from a German expert panel. Haemophilia. 2021;27(3):e305\u201313. https:\/\/doi.org\/10.1111\/hae.14010.","journal-title":"Haemophilia"},{"key":"2386_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100890","volume":"52","author":"C Hermans","year":"2021","unstructured":"Hermans C, Noone D, Benson G, Dolan G, Eichler H, Jim\u00e9nez-Yuste V, et al. Hemophilia treatment in 2021: choosing the\"optimal\" treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. Blood Rev. 2021;52:100890. https:\/\/doi.org\/10.1016\/j.blre.2021.100890.","journal-title":"Blood Rev"},{"issue":"Suppl 3","key":"2386_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/hae.14013","volume":"27","author":"CL Kempton","year":"2021","unstructured":"Kempton CL, Makris M, Holme PA. Management of comorbidities in haemophilia. Haemophilia. 2021;27(Suppl 3):37\u201345. https:\/\/doi.org\/10.1111\/hae.14013.","journal-title":"Haemophilia"},{"issue":"6","key":"2386_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000900","volume":"7","author":"REG Schutgens","year":"2023","unstructured":"Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, Klamroth R, et al. Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO clinical practice guidance. Hemasphere. 2023;7(6):e900. https:\/\/doi.org\/10.1097\/HS9.0000000000000900.","journal-title":"Hemasphere"},{"key":"2386_CR42","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jtha.2024.10.033","volume":"23","author":"M Scholzberg","year":"2025","unstructured":"Scholzberg M, Lassila R, Escobar M. Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the EHA-ISTH-EAHAD-ESO Clinical Practice Guidance document. J Thromb Haemost. 2025;23:745\u20139. https:\/\/doi.org\/10.1016\/j.jtha.2024.10.033.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2386_CR43","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/hae.15031","volume":"30","author":"PA Holme","year":"2024","unstructured":"Holme PA, Blatn\u00fd J, Chowdary P, Lassila R, O\u2019Connell N, Hermans C, et al. Moving towards normalization of haemostasis and health equity: evolving treatment goals for haemophilia A. Haemophilia. 2024;30(5):1109\u201314. https:\/\/doi.org\/10.1111\/hae.15031.","journal-title":"Haemophilia"},{"issue":"10480","key":"2386_CR44","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","volume":"405","author":"P Chowdary","year":"2025","unstructured":"Chowdary P, Carcao M, Kenet G, Pipe SW. Haemophilia. Lancet. 2025;405(10480):736\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(24)02139-1.","journal-title":"Lancet"},{"issue":"9","key":"2386_CR45","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJMp1109283","volume":"366","author":"MJ Barry","year":"2012","unstructured":"Barry MJ, Edgman-Levitan S. Shared decision making\u2013pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780\u20131. https:\/\/doi.org\/10.1056\/NEJMp1109283.","journal-title":"N Engl J Med"},{"issue":"10","key":"2386_CR46","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/bloodadvances.2025019054","volume":"10","author":"C Hermans","year":"2026","unstructured":"Hermans C, Chowdary P, Konkle BA, Mahlangu J, Facius A, Mancuso ME. A revised classification of FVIII concentrates: rationale and novel metrics. Blood Adv. 2026;10(10):3409\u201317. https:\/\/doi.org\/10.1182\/bloodadvances.2025019054.","journal-title":"Blood Adv"},{"issue":"11","key":"2386_CR47","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1007\/s12325-025-03336","volume":"42","author":"M Olivieri","year":"2025","unstructured":"Olivieri M, Yan S, Yang Y, Tomic R, Linhoff T, Zhang X, et al. Comparing real-world outcomes of prophylaxis with extended half-life factor IX (rIX-FP vs. rFIXFc and N9-GP) for haemophilia B: an analysis of medical chart data from Germany. Adv Ther. 2025;42(11):5696\u2013707. https:\/\/doi.org\/10.1007\/s12325-025-03336.","journal-title":"Adv Ther"},{"key":"2386_CR48","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/hae.13804","volume":"25","author":"A Tj\u00e4rnlund-Wolf","year":"2019","unstructured":"Tj\u00e4rnlund-Wolf A, Lassila R. Phenotypic characterisation of haemophilia B\u2014understanding the underlying biology of coagulation factor IX. Haemophilia. 2019;25:567\u201374. https:\/\/doi.org\/10.1111\/hae.13804.","journal-title":"Haemophilia"},{"issue":"8","key":"2386_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.103229","volume":"9","author":"C Hermans","year":"2025","unstructured":"Hermans C, Astermark J, Trakymien\u0117 S\u0160, Jim\u00e9nez-Yuste V. Haemophilia B: an illustrative review of current challenges and opportunities. Res Pract Thromb Haemost. 2025;9(8):103229. https:\/\/doi.org\/10.1016\/j.rpth.2025.103229.","journal-title":"Res Pract Thromb Haemost"},{"key":"2386_CR50","doi-asserted-by":"publisher","first-page":"204062072513989","DOI":"10.1177\/20406207251398986","volume":"17","author":"S Susen","year":"2026","unstructured":"Susen S, Kulkarni R, Nogami K, Peyvandi F, Konkle B, Santagostino E, et al. Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis. Ther Adv Hematol. 2026;17:20406207251398984. https:\/\/doi.org\/10.1177\/20406207251398986.","journal-title":"Ther Adv Hematol."},{"issue":"6","key":"2386_CR51","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1111\/hae.14649","volume":"28","author":"V Nummi","year":"2022","unstructured":"Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: comparison of factor product use, bleed rates and pharmacokinetics. Haemophilia. 2022;28(6):e237\u201344. https:\/\/doi.org\/10.1111\/hae.14649.","journal-title":"Haemophilia"},{"issue":"7","key":"2386_CR52","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/rth2.12421","volume":"4","author":"C Augustsson","year":"2020","unstructured":"Augustsson C, Norstr\u00f6m E, Andersson NG, Zetterberg E, Astermark J, Strandberg K. Monitoring standard and extended half-life products in hemophilia: assay discrepancies for factor VIII and IX in pre- and postinfusion samples. Res Pract Thromb Haemost. 2020;4(7):1114\u201320. https:\/\/doi.org\/10.1002\/rth2.12421.","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2386_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000911","volume":"7","author":"G Young","year":"2023","unstructured":"Young G. Nonfactor therapies for hemophilia. Hemasphere. 2023;7(6):e911. https:\/\/doi.org\/10.1097\/HS9.0000000000000911.","journal-title":"Hemasphere"},{"issue":"16","key":"2386_CR54","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2023022214","volume":"137","author":"MU Callaghan","year":"2021","unstructured":"Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1\u20134 studies. Blood. 2021;137(16):2231\u201342. https:\/\/doi.org\/10.1182\/blood.2023022214. (Blood. 2023 Oct 12;142(15):1329).","journal-title":"Blood"},{"issue":"3","key":"2386_CR55","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/hae.15015","volume":"30","author":"K van der Zwet","year":"2024","unstructured":"van der Zwet K, de Kovel M, Motwani J, van Geet C, Nolan B, Glosli H, et al. Bleeding control improves after switching to emicizumab: real-world experience of 177 children in the PedNet registry. Haemophilia. 2024;30(3):685\u201392. https:\/\/doi.org\/10.1111\/hae.15015.","journal-title":"Haemophilia"},{"issue":"5","key":"2386_CR56","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1111\/hae.14630","volume":"28","author":"S Arcudi","year":"2022","unstructured":"Arcudi S, Gualtierotti R, Marino S, Nicol\u00f2 G, Biguzzi E, Ciavarella A, et al. Real-world data on emicizumab prophylaxis in the Milan cohort. Haemophilia. 2022;28(5):e141\u20134. https:\/\/doi.org\/10.1111\/hae.14630.","journal-title":"Haemophilia"},{"issue":"14","key":"2386_CR57","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1182\/blood.2023021832","volume":"143","author":"SW Pipe","year":"2024","unstructured":"Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024;143(14):1355\u201364. https:\/\/doi.org\/10.1182\/blood.2023021832.","journal-title":"Blood"},{"issue":"2","key":"2386_CR58","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1111\/hae.14483","volume":"28","author":"AE Lehtinen","year":"2022","unstructured":"Lehtinen AE, Lassila R. Do we need all that emicizumab? Haemophilia. 2022;28(2):e53\u20135. https:\/\/doi.org\/10.1111\/hae.14483.","journal-title":"Haemophilia"},{"key":"2386_CR59","doi-asserted-by":"publisher","DOI":"10.1055\/a-2687-0107","author":"J M\u00fcller","year":"2025","unstructured":"M\u00fcller J, B\u00fcchsel M, Oleshko O, Pezeshkpoor B, Sachs U, Scholz U, et al. Laboratory monitoring in patients receiving emicizumab. Hamostaseologie. 2025. https:\/\/doi.org\/10.1055\/a-2687-0107.","journal-title":"Hamostaseologie"},{"issue":"4","key":"2386_CR60","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1111\/hae.14330","volume":"27","author":"T Szanto","year":"2021","unstructured":"Szanto T, Vaide I, Jouppila A, Lemponen M, Lassila R. Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway. Haemophilia. 2021;27(4):e571\u20134. https:\/\/doi.org\/10.1111\/hae.14330.","journal-title":"Haemophilia"},{"issue":"4","key":"2386_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102926","volume":"9","author":"RF Sidonio Jr","year":"2025","unstructured":"Sidonio RF Jr, Young G, Escuriola Ettingshausen C, Mahlangu J, Ozelo MC, Srivastava A, et al. Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice. Res Pract Thromb Haemost. 2025;9(4):102926. https:\/\/doi.org\/10.1016\/j.rpth.2025.102926.","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2386_CR62","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/hae.15062","volume":"30","author":"Y Xu","year":"2024","unstructured":"Xu Y, Wang Y, Wu R, Zheng C, Zhang L, Xu W, et al. Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicentre real-world study in China. Haemophilia. 2024;30(4):959\u201369. https:\/\/doi.org\/10.1111\/hae.15062.","journal-title":"Haemophilia"},{"issue":"4","key":"2386_CR63","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jtha.2023.12.023","volume":"22","author":"R Patil","year":"2024","unstructured":"Patil R, Shanmukhaiah C, Gogtay NJ, Pandey P, Patil K, Jijina F, et al. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients. J Thromb Haemost. 2024;22(4):1024\u201330. https:\/\/doi.org\/10.1016\/j.jtha.2023.12.023.","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2386_CR64","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood.2025031894","volume":"147","author":"K Nogami","year":"2026","unstructured":"Nogami K, You CW, Park YS, Chen YC, Shen MC, Wang JD, et al. NXTAGE: a phase 1\/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors. Blood. 2026;147(19):2261\u201371. https:\/\/doi.org\/10.1182\/blood.2025031894.","journal-title":"Blood"},{"issue":"6","key":"2386_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102181","volume":"7","author":"P Persson","year":"2023","unstructured":"Persson P, Amstrup AB, Coester HV, Matytsina I, Bas S. Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults. Res Pract Thromb Haemost. 2023;7(6):102181. https:\/\/doi.org\/10.1016\/j.rpth.2023.102181.","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2386_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.103333","volume":"10","author":"J Lund","year":"2026","unstructured":"Lund J, Ezban M, Jensen K, Lillicrap D. Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays. Res Pract Thromb Haemost. 2026;10(1):103333. https:\/\/doi.org\/10.1016\/j.rpth.2025.103333.","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"2386_CR67","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1616569","volume":"377","author":"KJ Pasi","year":"2017","unstructured":"Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377(9):819\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1616569.","journal-title":"N Engl J Med"},{"issue":"7","key":"2386_CR68","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/17474086.2025.2519002","volume":"18","author":"J Mahlangu","year":"2025","unstructured":"Mahlangu J. Anti-tissue factor pathway inhibitors for hemophilia: are these treatments the answer to overcoming current treatment limitations? Expert Rev Hematol. 2025;18(7):521\u20137. https:\/\/doi.org\/10.1080\/17474086.2025.2519002.","journal-title":"Expert Rev Hematol"},{"issue":"25","key":"2386_CR69","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1182\/blood.2024027008","volume":"145","author":"G Young","year":"2025","unstructured":"Young G, Kavakli K, Klamroth R, Matsushita T, Peyvandi F, Pipe SW, et al. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 2025;145(25):2966\u201377. https:\/\/doi.org\/10.1182\/blood.2024027008.","journal-title":"Blood"},{"issue":"11","key":"2386_CR70","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1182\/bloodadvances.2021006403","volume":"6","author":"AD Shapiro","year":"2022","unstructured":"Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H, et al. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors. Blood Adv. 2022;6(11):3422\u201332. https:\/\/doi.org\/10.1182\/bloodadvances.2021006403.","journal-title":"Blood Adv"},{"issue":"1","key":"2386_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16720-9","volume":"11","author":"XY Zhao","year":"2020","unstructured":"Zhao XY, Wilmen A, Wang D, Wang X, Bauzon M, Kim JY, et al. Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia. Nat Commun. 2020;11(1):2992. https:\/\/doi.org\/10.1038\/s41467-020-16720-9.","journal-title":"Nat Commun"},{"issue":"5","key":"2386_CR72","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.jtha.2024.01.017","volume":"22","author":"C Dix","year":"2024","unstructured":"Dix C, Dolan G, Hunt BJ. Reducing the risk of atherosclerotic cardiovascular disease in people with hemophilia: the importance of primary prevention. J Thromb Haemost. 2024;22(5):1304\u201312. https:\/\/doi.org\/10.1016\/j.jtha.2024.01.017.","journal-title":"J Thromb Haemost"},{"issue":"18","key":"2386_CR73","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","volume":"365","author":"C Leissinger","year":"2011","unstructured":"Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365(18):1684\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1104435.","journal-title":"N Engl J Med"},{"issue":"6","key":"2386_CR74","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/hae.15100","volume":"30","author":"D Coffin","year":"2024","unstructured":"Coffin D, Skinner MW, Thornburg CD, Hayes BK, Sanni\u00e9 T, Kaeser GE, et al. Development of the World Federation of Hemophilia Shared Decision-Making Tool. Haemophilia. 2024;30(6):1298\u2013308. https:\/\/doi.org\/10.1111\/hae.15100.","journal-title":"Haemophilia"},{"key":"2386_CR75","doi-asserted-by":"publisher","first-page":"204062072312023","DOI":"10.1177\/2040620723120230","volume":"14","author":"J Astermark","year":"2023","unstructured":"Astermark J, Baghaei F, Strandberg K, Toplican PG, Birkedal MF, Grahn E, et al. Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context. Ther Adv Hematol. 2023;14:20406207231202304. https:\/\/doi.org\/10.1177\/2040620723120230.","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"2386_CR76","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/hae.14985","volume":"30","author":"W Miesbach","year":"2024","unstructured":"Miesbach W, Boban A, Chowdary P, Coppens M, Crato M, Jimenez-Yuste V, et al. Administration of gene therapy for haemophilia - the hub and spoke model and its regional differences and challenges. Haemophilia. 2024;30(3):855\u20137. https:\/\/doi.org\/10.1111\/hae.14985.","journal-title":"Haemophilia"},{"issue":"1","key":"2386_CR77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/a-2751-7625","volume":"46","author":"W Miesbach","year":"2026","unstructured":"Miesbach W. Gene therapy of haemophilia: current status and future directions. Hamostaseologie. 2026;46(1):10\u20136. https:\/\/doi.org\/10.1055\/a-2751-7625.","journal-title":"Hamostaseologie"},{"key":"2386_CR78","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","volume":"392","author":"UM Reiss","year":"2025","unstructured":"Reiss UM, Davidoff AM, Tuddenham EGD, Chowdary P, McIntosh J, Muczynski V, et al. Sustained clinical benefit of AAV gene therapy in severe hemophilia B. N Engl J Med. 2025;392:2226\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2414783.","journal-title":"N Engl J Med"},{"issue":"7","key":"2386_CR79","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/17474086.2024.2365929","volume":"17","author":"S Benemei","year":"2024","unstructured":"Benemei S, Boni L, Castaman G. Outcome measures in hemophilia: current and future perspectives. Expert Rev Hematol. 2024;17(7):329\u201340. https:\/\/doi.org\/10.1080\/17474086.2024.2365929.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2386_CR80","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/hae.14167","volume":"27","author":"V Jim\u00e9nez-Yuste","year":"2021","unstructured":"Jim\u00e9nez-Yuste V, Auerswald G, Benson G, Dolan G, Hermans C, Lambert T, et al. Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors. Haemophilia. 2021;27(3):340\u201350. https:\/\/doi.org\/10.1111\/hae.14167.","journal-title":"Haemophilia"},{"key":"2386_CR81","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.2147\/IJGM.S464226","volume":"17","author":"K Batt","year":"2024","unstructured":"Batt K, Klamroth R, Mancuso ME, Tiede A, Mantovani LG. The importance of clinical context and consistency in methodology when using matching-adjusted indirect comparisons (MAICs) to compare outcomes. Int J Gen Med. 2024;17:3927\u201332. https:\/\/doi.org\/10.2147\/IJGM.S464226.","journal-title":"Int J Gen Med"},{"issue":"5","key":"2386_CR82","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3324\/haematol.2022.282099","volume":"109","author":"PE Alcedo Andrade","year":"2024","unstructured":"Alcedo Andrade PE, Mannucci PM, Kessler CM. Emicizumab: the hemophilia A game-changer. Haematologica. 2024;109(5):1334\u201347. https:\/\/doi.org\/10.3324\/haematol.2022.282099.","journal-title":"Haematologica"},{"key":"2386_CR83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/JBM.S288283","volume":"12","author":"R Klamroth","year":"2021","unstructured":"Klamroth R, Wojciechowski P, Aball\u00e9a S, Diamand F, Hakimi Z, Nazir J, et al. Efficacy of rFVIIIFc versus emicizumab for the treatment of patients with hemophilia A without inhibitors: matching-adjusted indirect comparison of A-LONG and HAVEN trials. J Blood Med. 2021;12:115\u201322. https:\/\/doi.org\/10.2147\/JBM.S288283.","journal-title":"J Blood Med"},{"issue":"6","key":"2386_CR84","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/jth.14784","volume":"18","author":"F Peyvandi","year":"2020","unstructured":"Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M. Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemost. 2020;18(6):1242\u201355. https:\/\/doi.org\/10.1111\/jth.14784.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2386_CR85","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","volume":"4","author":"PJ Lenting","year":"2020","unstructured":"Lenting PJ. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv. 2020;4(9):2111\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2019000849.","journal-title":"Blood Adv"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02386-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:12:01Z","timestamp":1792829521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02386-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":85,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2386"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02386-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following interests during the past 3 years: TS received honoraria for advisory activities and lectures from CSL Behring, Octapharma, Pfizer, Roche, and Sobi. RL is the chief strategic officer (CSO) and chief medical officer (CMO) of Aplagon Ltd, a drug development company for thromboinflammatory diseases. She received honoraria for advisory activities and lectures from Biomarin, CSL Behring, LFB, Octapharma, Pfizer, Roche, Sanofi, Sobi, and Takeda.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ChatGPT has been occasionally used for language editing.","order":7,"name":"Ethics","label":"Artificial intelligence","group":{"name":"EthicsHeading","label":"Declarations"}}]}}